Page last updated: 2024-11-05

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Disease Exacerbation

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole has been researched along with Disease Exacerbation in 1 studies

3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole: antineoplastic; activates platelet guanylate cyclase; a radiosensitizing agent and guanylate cyclase activator; structure in first source
lificiguat : A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhu, H1
Feng, Y1
Zhang, J1
Zhou, X1
Hao, B1
Zhang, G1
Shi, R1

Other Studies

1 other study available for 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole and Disease Exacerbation

ArticleYear
Inhibition of hypoxia inducible factor 1α expression suppresses the progression of esophageal squamous cell carcinoma.
    Cancer biology & therapy, 2011, Jun-01, Volume: 11, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor;

2011